U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H16O6.C11H14N2S
Molecular Weight 594.677
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of PYRANTEL PAMOATE

SMILES

CN1CCCN=C1\C=C\C2=CC=CS2.OC(=O)C3=CC4=C(C=CC=C4)C(CC5=C6C=CC=CC6=CC(C(O)=O)=C5O)=C3O

InChI

InChIKey=AQXXZDYPVDOQEE-MXDQRGINSA-N
InChI=1S/C23H16O6.C11H14N2S/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h1-10,24-25H,11H2,(H,26,27)(H,28,29);2,4-6,9H,3,7-8H2,1H3/b;6-5+

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/monograph/pyrantel-pamoate.html

Pyrantel is an anthelmintic, which acts as an agonist of nicotinic receptors (AChRs) of nematodes and exerts its therapeutic effects by depolarizing their muscle membranes. It is used to treat a number of parasitic worm infections. This includes ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis and trichinellosis. Common adverse reactions include diarrhea, nausea, vomiting, dizziness, headache and somnolence.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Strongid

Approved Use

Drug is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum) in horses and ponies.

Launch Date

1990
Curative
Strongid

Approved Use

Drug is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum) in horses and ponies.

Launch Date

1990
Curative
Strongid

Approved Use

Drug is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); and large roundworms (Parascaris equorum) in horses and ponies.

Launch Date

1990
Curative
Strongid

Approved Use

Pyrantel pamoate is indicated for the removal and control of mature infections of large strongyles (Strongylus vulgaris, S. edentatus, S. equinus); small strongyles; pinworms (Oxyuris equi); large roundworms (Parascaris equorum) and tapeworms (Anoplocephala perfoliata) in horses and ponies.

Launch Date

1990
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.09 μg/mL
13.3 mg/kg single, oral
dose: 13.3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
PYRANTEL plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.06 μg × h/mL
13.3 mg/kg single, oral
dose: 13.3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
PYRANTEL plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.43 h
13.3 mg/kg single, oral
dose: 13.3 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
PYRANTEL plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s.
2001 Jan
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.
2003 Sep
Patents

Sample Use Guides

A modified methyl-thiazolyltetrazolium (MTT) reduction assay revealed good in vitro anthelmintic efficacies against Haemonchus contortus infective larvae for pyrantel tartrate at effective dose 0.1 ug/ul – 0.9 ug/ul.
Name Type Language
PYRANTEL PAMOATE
GREEN BOOK   MI   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
CP 10423-16
Code English
Pyrantel embonate [WHO-DD]
Common Name English
PYRANTEL PAMOATE [GREEN BOOK]
Common Name English
PYRANTEL EMBONATE [EP MONOGRAPH]
Common Name English
CP-10,423-16
Code English
PYRIMIDINE, 1,4,5,6-TETRAHYDRO-1-METHYL-2-(2-(2-THIENYL)ETHENYL)-, (E)-, COMPD. WITH 4,4'-METHYLENEBIS(3-HYDROXY-2-NAPHTHALENECARBOXYLIC ACID) (1:1)
Common Name English
PYRANTEL PAMOATE [VANDF]
Common Name English
PYRANTEL PAMOATE [MI]
Common Name English
CP-10423-18
Code English
PYRANTEL (AS PAMOATE)
Common Name English
PYRANTELI EMBONAS [WHO-IP LATIN]
Common Name English
PYRANTEL EMBONATE
EP   MART.   WHO-DD   WHO-IP  
Common Name English
PYRANTEL PAMOATE [USP-RS]
Common Name English
PYRANTEL EMBONATE [WHO-IP]
Common Name English
CP-10423-16
Code English
(E)-1,4,5,6-TETRAHYDRO-1-METHYL-2-(2-(2-THIENYL)VINYL)PYRIMIDINE 4,4'-METHYLENEBIS(3-HYDROXY-2-NAPHTHOATE) (1:1)
Common Name English
NSC-355080
Code English
PYRANTEL PAMOATE [USAN]
Common Name English
PYRANTEL PAMOATE [USP MONOGRAPH]
Common Name English
PYRANTEL PAMOATE [JAN]
Common Name English
PYRANTEL EMBONATE [MART.]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 357.152
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
CFR 21 CFR 520.1872
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
CFR 21 CFR 520.2043
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
CFR 21 CFR 357.180
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
CFR 21 CFR 357.150
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
CFR 21 CFR 520.2044
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
NCI_THESAURUS C250
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
CFR 21 CFR 357.110
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
CFR 21 CFR 520.2042
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
CFR 21 CFR 520.2041
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID40897057
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
MERCK INDEX
m9336
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY Merck Index
WIKIPEDIA
PYRANTEL PAMOATE
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
DAILYMED
81BK194Z5M
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
MESH
D011716
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
PYRANTEL PAMOATE
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY Description: A pale yellow or yellow powder. Solubility: Practically insoluble in water and methanol R; soluble in dimethyl sulfoxide R; slightly soluble in dimethylformamide R. Category: Anthelmintic. Storage: Pyrantel embonate should be kept in a well-closed container, protected from light. Definition: Pyrantel embonate contains not less than 98.0% and not more than 102.0% of C11H14N2S,C23H16O6, calculated with reference to the dried substance.
SMS_ID
100000089059
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
RXCUI
8985
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY RxNorm
PUBCHEM
5281033
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
FDA UNII
81BK194Z5M
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
ECHA (EC/EINECS)
244-837-1
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
NCI_THESAURUS
C75232
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
NSC
355080
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
ChEMBL
CHEMBL1626223
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
RS_ITEM_NUM
1584003
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
DRUG BANK
DBSALT001530
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
CAS
22204-24-6
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY
EVMPD
SUB04132MIG
Created by admin on Fri Dec 15 15:09:05 GMT 2023 , Edited by admin on Fri Dec 15 15:09:05 GMT 2023
PRIMARY